BeiGene to Present at Cowen and Company 36th Annual Health Care Conference

BEIJING, March 01, 2016 -- BeiGene, Ltd. (Nasdaq:BGNE), a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that it will present at the Cowen and Company 36^th Annual Health Care Conference in Boston, MA.

John V. Oyler, Founder and Chief Executive Officer, and Howard Liang, Ph.D., Chief Financial Officer and Chief Strategy Officer, will deliver a corporate overview at 2:00 p.m. EST on Monday, March 7, 2016.

A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/.  An archived replay will be available for 90 days following the event.

About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and a lasting impact on cancer patients.

Media/Investor Contact:

Lucy Li, PhD
Associate Director of Strategy and Investor Relations
781-801-1800
[email protected]
[email protected]